BIOCAUSE HEILEN PHARMA: Febuxostat tablets have obtained a drug registration certificate
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, for the drug Febuxostat Tablets. Febuxostat Tablets are a xanthine oxidase inhibitor, primarily used for the long-term treatment of hyperuricemia and gout patients (including urate-lowering treatment after acute attacks of gouty arthritis)
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The related drug is Febuxostat Tablets. Febuxostat Tablets are a xanthine oxidase inhibitor, mainly used for the long-term treatment of hyperuricemia and gout patients (including urate-lowering treatment after acute attacks of gouty arthritis)
